학술논문
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
Document Type
Journal Article
Author
Akinori Asagi; Akio Nakasya; Chihiro Sakaguchi; Ichinosuke Hyodo; Kaori Hino; Kaori Marui; Kozue Kanemitsu; Masahito Kokubu; Megumi Yoshimatsu; Mitsuhito Koizumi; Norifumi Nishide; Seijin Nadano; Takashi Terao; Takeshi Kajiwara; Teru Kumagi; Tomohiro Nishina; Tomonori Inoue; Yoichi Hiasa; Yoshiki Imamura; Yusuke Okujima; Yuuki Numata
Source
Internal Medicine. 2022, 61(15):2255
Subject
Language
English
ISSN
0918-2918
1349-7235
1349-7235
Abstract
Results Compared to S-1, mFFX tended to be used for younger patients with a good general condition (median age, 63 vs. 71 years, p<0.01; and performance status 0, 67% vs. 37%, p<0.05). The median progression-free and overall survival were similar between the S-1 (3.7 and 7.2 months, respectively) and mFFX (3.3 and 7.4 months, respectively) groups. The response rate in patients with measurable lesions was 4% (n=1/23) in the S-1 group and 17% (n=2/12) in the mFFX group. The incidence of grade 3 or 4 adverse events was 20% in the S-1 group and 57% (neutrophil count decreased in 43%) in the mFFX group (p<0.01).